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Denis H.Y. Leung, Ph.D., Maria E. Dudas, Aviram Nissan, M.D., Carlos Cordon-Cardo, M.D.,
Ronald A. Ghossein, M.D.
Departments of Surgery (MFB, AH, AN) and Pathology (AH, AO, MeD, CC-C, RAG), Memorial Sloan-
Kettering Cancer Center, New York, New York; Department of Surgery (AS), Walter Reed Army Medical
Center, Washington, D.C.; and School of Economics and Social Sciences (DHYL), Singapore Management
University, Singapore
We compared histomorphological features andmo-
lecular expression profiles of adrenocortical adeno-
mas (ACAd) and carcinomas (ACCa). A critical his-
topathological review (mean, 11 slides per patient)
was conducted of 37 ACAd and 67 ACCa. Paraffin-
embedded tissue cores of ACAd (n  33) and ACCa
(n  38) were arrayed in triplicate on tissue mi-
croarrays. Expression profiles of p53, mdm-2, p21,
Bcl-2, cyclin D1, p27, and Ki-67 were investigated by
immunohistochemistry and correlated with histo-
pathology and patient outcome using standard sta-
tistical methodology. Median follow-up period was
5 years. Tumor necrosis, atypical mitoses, and >1
mitosis per 50 high-power fields were factors that
were highly specific for ACCa (P < .001). Number (0
to 4) of unfavorable markers [Ki-67 (), p21 (),
p27 (), mdm-2()] expressed was significantly as-
sociated with mitotic activity and morphologic in-
dex (i.e., number of adverse morphologic features)
and highly predictive of malignancy (P < .001).
Ki-67 overexpression occurred in 0 ACAd and 36%
ACCa (P < .001) and was significantly associated
with mitotic rate and unfavorable morphologic in-
dex (P< .001). Tumor necrosis, atypicalmitoses,>5
mitoses per 50 high-power fields, sinusoidal inva-
sion, histologic index of >5, and presence of more
than two unfavorable molecular markers were as-
sociated significantly withmetastasis in ACCa.Well-
established histopathologic criteria and Ki-67 can
specifically distinguish ACCAd from ACCa. Tumor
cell proliferation (Ki-67) correlates with mitotic ac-
tivity andmorphologic index. Tumormorphology is
a better predictor of metastatic risk in ACCa than
current immunohistochemistry-detected cell cycle
regulatory and proliferation–associated proteins.
KEY WORDS: Adenoma, Adrenal, Carcinoma, IHC,
Tissue microarray.
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Adrenocortical carcinoma is a highly aggressive,
rare endocrine malignancy. However, benign, clin-
ically occult adrenal adenomas, adrenal “inciden-
talomas,” are encountered frequently by abdominal
imaging performed for unrelated indications. The
unsuspected adrenal mass is detected in 2–4% of
the general population and in 6% of abdominal
computed tomography scans in patients aged
60–70 years (1, 2). The size of the adrenal mass is
considered to be the most reliable predictor of ma-
lignancy. As 8–13.5% of resected adrenocortical
carcinomas are 5 cm, size alone is an imperfect
criterion for malignancy (3).
In a study of metastasizing and nonmetastasizing
adrenocortical tumors among 43 patients followed
for a median of 11 years, Weiss (4) demonstrated
the utility of nine histomorphologic criteria in pre-
dicting the biology of adrenocortical neoplasms.
The histologic findings most predictive of malig-
nancy were 5 mitoses per 50 high-power fields,
atypical mitoses, and venous invasion. No single
criterion could distinguish benign from malignant
tumor biology; all but one of the benign adrenocor-
tical tumors had two or fewer criteria. In a later
study, Weiss et al. (5) modified the diagnostic cri-
teria for benign and malignant adrenocortical neo-
plasms; tumors exhibiting three or more adverse
histologic features were considered malignant. A
recent study identified six morphologic prognostic
factors that correlated significantly with disease-
specific survival in adrenocortical carcinoma: ve-
nous, capsular, and adjacent organ invasion; tumor
Copyright © 2003 by The United States and Canadian Academy of
Pathology, Inc.
VOL. 16, NO. 8, P. 742, 2003 Printed in the U.S.A.
Date of acceptance: May 1, 2003.
Address reprint requests to: Alexander Stojadinovic, M.D., Walter Reed Army
Medical Center, General Surgery Service, 6900 Georgia Avenue, N.W., Wash-
ington, D.C. 20307; fax: 202-782-1234; e-mail: ta.stojadinovic@verizon.net.
DOI: 10.1097/01.MP.0000081730.72305.81
742
necrosis and mitotic rate; and atypical mitosis (6).
Both studies identified mitotic activity as the single
most important determinant of tumor-related mor-
tality from adrenocortical carcinoma (5, 6).
Difficulty remains in differentiating benign from
malignant adrenal tumors, particularly in large tu-
mors without invasive features and cellular atypia
(7). Nuclear DNA content by flow cytometry corre-
lates poorly with histological and mitotic indices
and cannot reliably differentiate between adreno-
cortical adenoma and carcinoma (8). P53 tumor
suppressor gene alterations have been shown to
have variable expression and little prognostic value
for adrenocortical carcinoma (8–10). Immunohis-
tochemical analyses of antigens that serve as mark-
ers of cell proliferation—Ki67, PCNA, and epider-
mal growth factor receptor—have demonstrated
relatively increased expression of these proteins in
adrenocortical carcinoma (11–16). No consistent
correlations between these cell cycle proteins and
histopathology, mitotic index, and outcome could
be identified (16).
Multimolecular profiling using immunohisto-
chemical analysis of tissue microarrays has been
shown to be an efficient, reproducible, and valid
method to study cell cycle regulatory proteins in
endocrine neoplasms (6, 17–19). In the present
study, tissue microarrays and immunohistochemi-
cal analysis are applied to a cohort of adrenal tu-
mors. The main objective of the study is to define
molecular phenotypes of potential value in distin-
guishing benign from malignant adrenocortical
neoplasms. For that purpose, we compared a group
of adrenocortical carcinomas about which we pre-
viously published (6) with a group of adrenocortical
adenomas from our institution.
MATERIALS AND METHODS
Patient Search and Inclusion and Exclusion
Criteria
We identified 67 consecutively treated patients
with histologically confirmed adrenocortical carci-
noma from the Memorial Sloan-Kettering Cancer
Center Prospective Endocrine Tumor Database. All
patients underwent resection of primary adreno-
cortical carcinoma and had histopathologic slides
available for review. Paraffin-embedded blocks
were available for 38 of these patients. We reported
on the above-mentioned group of adrenocortical
carcinoma patients in a prior publication (6). A
search of the Memorial Sloan-Kettering Cancer
Center Department of Pathology computerized da-
tabase was conducted using the terms adrenal and
adenoma, identifying 60 patients treated surgically
for adrenal adenomas between the years 1990 and
1998. Patients with nonadrenocortical tumors, or
those with adrenal hyperplasia or metastasis to the
adrenal gland and those having only fine-needle
aspiration or biopsy of the adrenal were excluded,
leaving 37 patients treated with adrenalectomy with
available slides for review. Paraffin blocks were
available for 33 cases. All available clinical, patho-
logical, treatment, and follow-up data were re-
viewed and were updated for 104 patients who un-
derwent adrenalectomy for either adrenocortical
adenoma or carcinoma. The role of re-resection
and prognostic variables for adrenocortical carci-
noma were the subjects of previous reports from
our institution (20, 21). We later defined the molec-
ular phenotype of normal adrenal tissue and ma-
lignant adrenal tumors and compared the morpho-
logic and molecular parameters with one another
and correlated these factors with patient outcome
in a multivariate analysis (6). The purpose of the
present study is to compare the histological fea-
tures and multimolecular phenotypes of benign
and malignant adrenocortical neoplasms.
Treatment
All patients underwent primary treatment ac-
cording to standard of care at Memorial Sloan-
Kettering Cancer Center with adrenalectomy with
or without concomitant solid-organ (pancreas,
spleen, kidney, and/or liver) resection as necessary
to achieve complete resection of all grossly evident
disease. Adjuvant treatment in the form of radio-
therapy or chemotherapy was administered as part
of standard of care or as part of clinical trials.
Pathologic Review
All available operative reports and information in
the institutional pathology database and pathology
reports of the primary tumor were reviewed to con-
firm completeness of resection. All available au-
topsy reports were reviewed. Two members (RAG
and AO) of the pathology department conducted a
critical histopathological review of all available
slides. A mean of 11 hematoxylin-eosin slides per
patient was reviewed in conjunction with the cor-
responding pathologic record but without knowl-
edge of clinical data. All histologically confirmed
adrenocortical adenomas and carcinomas were in-
cluded in the analysis. All adrenocortical tumors
were evaluated according to the following patho-
logic criteria: gross tumor size and weight, nuclear
grade, mitotic rate per 50 high power fields (hpf),
tumor cell cytoplasm (0–25% and 26–100% clear)
and architecture (diffuse and nondiffuse), presence
or absence of atypical mitoses, necrosis, and un-
equivocal capsular, venous, sinusoidal and adja-
cent organ invasion (4, 5). All adrenocortical carci-
nomas in this study had three or more of Weiss’
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histologic criteria (4). Mitotic rate was determined
by counting 50 high-power fields (400) with an
Olympus microscope (U-DO model). The regions of
the slide selected were those containing the highest
concentrations of mitotic figures. Each 10 high-
power fields were counted on a different slide as
feasible. Architecture was defined as “diffuse” when
sheets of cells without a characteristic pattern of
growth comprised 33% of the tumor; otherwise,
the architecture was categorized as nondiffuse. En-
dothelial lined vessels with muscle comprising the
vessel wall were regarded as a vein, unlike sinu-
soids, endothelial lined vessels with little support-
ing tissue. A vein or sinusoid within or external to
the adrenal tumor that contained tumor cells
within its lumen and was adherent to its wall de-
fined venous or sinusoidal invasion. A tumor com-
pletely penetrating the surrounding capsule de-
fined unequivocal capsular invasion.
Clinicopathological Categories
Clinical data included patient age, gender, pre-
senting symptoms, functional endocrine tumor ac-
tivity, history of prior malignancy, and radiologic
tumor size. During the histopathologic review, mi-
croscopic resection margins as well as the 11 pre-
viously noted morphologic criteria of Weiss (4) were
recorded. Molecular markers studied included Ki-
67, p53, mdm-2, p21, p27, bcl-2, and cyclin D1.
Definitions
A primary tumor was defined as a previously
untreated, or biopsied (needle aspiration, inci-
sional, or inadequate excisional biopsy), mass be-
fore definitive surgical therapy. Patients were con-
sidered to have prior cancer if they had a
histologically confirmed malignancy other than
nonmelanoma skin cancers or carcinoma in situ of
the cervix before diagnosis of the adrenal neo-
plasm. An adrenal neoplasm was considered func-
tional when biochemical analysis confirmed excess
adrenocortical hormone secretion. Complete surgi-
cal resection was defined as the absence of gross
residual disease after surgical excision of the adre-
nal tumor. Microscopic margins were defined at the
time of initial histopathological assessment and
confirmed at time of re-review. Microscopic resec-
tion margins were categorized as positive (tumor at
the inked margin) or negative (no tumor at the
inked margin). Follow-up was calculated from the
time of primary operation to the date of last
follow-up.
Tissue Microarray Construction and
Immunohistochemistry
Paraffin-embedded blocks were available for 33
and 38 patients with adrenocortical adenoma and
carcinoma, respectively. Five-micrometer
hematoxylin/eosin-stained sections of paraffin-
embedded sections of benign and malignant adre-
nocortical tissue were reviewed to confirm diagno-
sis and target areas of the block for tissue
microarray construction, from which 0.6-mm-
diameter core biopsies were taken with a precision
instrument (Beecher Instruments, Silver Spring,
MD) as described elsewhere (19, 22). Tissue cores
were arrayed in triplicate on a recipient paraffin
block (22). Five-micrometer sections of these tissue
array blocks were cut and placed on charged poly-
lysine–coated slides. These sections were used for
immunohistochemical analysis as described else-
where (6, 17–19). Tissues and cell lines known to
express the antigens of interest were used as posi-
tive controls. Normal tissues were included on the
microarray and were used as baseline controls.
Sections from tissue arrays were deparaffinized,
rehydrated in graded alcohols, and processed using
the avidin-biotin immunoperoxidase method. The
sections underwent microwave oven treatment for
15 minutes in 0.01 M-citrate buffer at pH 6.0. This
procedure was followed for all antibodies used in
this study, with the exception of Ki-67 antibody that
was incubated in preheated 0.05% trypsin, 0.05%
CaCl2 in 0.05 M Tris-HCl (pH 7.6) for 5 minutes at
37° C before microwave treatment. After antigen
retrieval, slides were incubated in 10% normal
horse serum for 30 minutes, then incubated over-
night at 4° C in appropriately diluted primary anti-
body. Mouse anti-human monoclonal antibodies to
p53 (Ab-2, clone 1801, 1:500 dilution; Calbiochem,
Cambridge, MA), mdm-2 (clone 2A10, 1:500 dilu-
tion; provided by Dr. A. Levine, Rockefeller Univer-
sity, New York), p21 (WAF-1 [Ab-1], clone EA10,
1:100 dilution; Calbiochem), p27 (kip-1 [Ab-2],
clone DCS72, 1:500 dilution; Oncogene Research
Products, Cambridge, MA), cyclin D1 (Ab-3, clone
DCS-6, 1:100 dilution; Calbiochem), Ki-67 (clone
Mib-1, 1:1000 dilution; DAKO, Glostrup, Denmark),
and Bcl-2 (clone 124, 1:154 dilution; DAKO) were
used. The anti-p53 antibody detects wild-type and
mutated p53. Samples were then incubated with
biotinylated anti-mouse immunoglobulins at 1:500
dilution (Vector Laboratories, Inc., Burlingame,
CA), followed by avidin-biotin peroxidase com-
plexes (1:25, Vector Laboratories, Inc.) for 30 min-
utes. Diaminobenzidine was used as the chromo-
gen, and hematoxylin, as the nuclear counterstain.
Rates of lost cases attributable to tissue damage
ranged between 1 and 10% for the different molec-
ular markers. Immunoreactivity was classified as
continuous data (undetectable levels, 0, to homo-
geneous staining, 100%) for all markers. Two inves-
tigators (RAG, AO) reviewed and scored slides inde-
pendently by estimating the percentage of tumor
cells showing characteristic staining. The cutoff val-
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ues for tumor cell staining used in the present study
were defined based on previously established cutoff
values used in prior clinicopathological studies of
endocrine neoplasms employing identical reagents
(6, 17, 18). Evaluation of microarray-based data was
performed according to a previously established
and validated system (19). The cutoff values for
tumor cell staining used for all adrenocortical neo-
plasms in this study were defined as follows: (1)
high Ki-67 proliferative index if 5% tumor nuclei
stained; (2) p53 nuclear overexpression if 5% tu-
mor nuclei stained; (3) mdm-2 overexpression if
50% tumor nuclei stained; (4) p21 nuclear over-
expression if 10% of tumor nuclei stained; (5) p27
nuclear overexpression if 30% nuclei stained; (6)
Bcl-2 overexpression if 50% of tumor cells dem-
onstrated cytoplasmic staining; and (7) cyclin D1
overexpression if 5% of tumor nuclei stained. Tu-
mors were then grouped into binary categories de-
fined as follows: negative expression (neoplasms be-
low defined cutoff value of immunoreactivity) and
positive expression (neoplastic tissues above de-
fined cutoff values of immunoreactivity).
Statistics
Associations between categorical variables were
evaluated using the Fisher’s exact test when fre-
quency was small and were carried out using the 2
test with Yates’ correction when frequency was
large enough to justify its use. The Cochran-
Armitage test was used to test for trends. Nonpara-
metric comparison of median values across groups
was performed for continuous variables using the
Wilcoxon/Kruskall-Wallis rank-sum tests. To assess
the independent predictive effect of a covariate (tu-
mor size or mitotic rate, for example) for a nominal
response (in this case malignancy), a logistic regres-
sion model was constructed and parameters were
estimated using maximum likelihood. No multivar-
iate analyses were performed for the clinical end-
points because of the moderate number of cases
and the fact that only very few cases had not devel-
oped the endpoint. The likelihood ratio test was
computed for each effect in the model. Confidence
limits and odds ratios were calculated for the max-
imum likelihood parameter estimates. Many of the
variables, such as mitotic index and molecular
markers, had skewed distributions with a large
number of ties at the lower end of their range. For
information purposes, the median of the variables
is reported where appropriate, but for purpose of
analysis, they were analyzed as categorical vari-
ables. Statistical analysis was performed using the
JMP statistical package (JMP, Cary, NC). A P value
of .05 was considered significant.
RESULTS
Clinical Features
Median follow-up for those alive at time of last
clinic visit was 5.5 years (range, 1.2–16.9 y). The
majority (78.4%) of benign adrenal tumors were
identified among patients with previously treated
nonadrenal malignancy during cross-sectional im-
aging. Adrenalectomy in these patients was per-
formed on the basis of increased suspicion of
single-site metachronous distant metastasis. Three
(8.1%) of these patients were found to have asymp-
tomatic functional tumors during biochemical test-
ing. The fact that functional adrenocortical neo-
plasms were associated with higher mitotic (79% vs.
28%, 5 per 50 high-power field, P  .001) and
Ki-67 overexpression (29% vs. 8%, positive, P  .1)
than nonfunctional tumors likely reflects the in-
creased proportion of hormonally active malignant
to benign lesions (45% vs. 8%, P  .001). Median
primary tumor size of adrenocortical carcinoma
significantly exceeded that of adrenal adenoma
(14.5 vs. 2.5 cm, P  .001). Median size of the
adrenal tumors was significantly higher, with high
mitotic activity (3.6 vs. 14.9 cm: 5 vs. 5 per 50
high-power fields, P  .001) and Ki-67 overexpres-
sion (15 vs. 4 cm: [] vs. [-] Ki67, P  .001). See
Table 1 for a summary of these features.
Morphology
No benign and 91% of malignant tumors ex-
ceeded 100 g in weight (P  .001). Although no
adenoma in this study had histologic evidence of
venous, capsular, sinusoidal, or adjacent organ in-
vasion, these findings were identified in 42%, 53%,
94%, and 8% of adrenocortical carcinomas (P 
.001). The majority (87%) of adrenal adenomas
TABLE 1. Adrenal Adenoma versus Carcinoma, Clinical
Features
Characteristic
Adenoma
(n  37)
n (%)
ACC
(n  67)
n (%)
P
Gender 0.721
Female 23 (62.2%) 44 (65.7%)
Male 14 (37.8%) 23 (34.3%)
Median age, years (range) 62 (41–84) 47 (2–77) 0.001
Symptoms 0.001
Asymptomatic 31 (83.8%) 2 (2.9%)
Endocrine 3 (8.1%) 30 (44.8%)
Pain 0 (0.0%) 14 (20.9%)
Palpable mass 0 (0.0%) 3 (4.5%)
Other 0 (0.0%) 5 (7.5%)
Unknown 3 (8.1%) 13 (19.4%)
Tumor status 0.001
Secretory 3 (8.1%) 30 (44.8%)
Non-secretory 31 (83.8%) 24 (35.8%)
Unknown 3 (8.1%) 13 (19.4%)
Coexisting malignancy 29 (78.4%) N/A N/A
Median tumor size, cm (range) 0.001
2.5 (0.9–7.0) 14.5 (4.0–28.5)
Phenotyping of Adrenal Tumors (A. Stojadinovic et al.) 745
demonstrated nuclear features consistent with Fu-
hrman nuclear Grade 1 or 2; these findings were
evident in only one (1.5%) adrenal carcinoma (P 
.001). Tumor necrosis and atypical mitotic figures
were seen exclusively in adrenocortical carcinomas.
Mitotic figures were observed in all but two
(3.0%) primary adrenal malignancies. A single mi-
totic figure was identified among 1850 high-power
fields examined in adrenocortical adenomas. Al-
though not specific for malignancy, mitotic figures
were an infrequent finding among benign adrenal
tumors (3% vs. 97%, P  .001). Mitosis of 1 per 50
high-power fields was specific for adrenocortical
carcinoma in this patient cohort.
Most (82%) malignant adrenal tumors had diffuse
architecture consisting of sheets of cells without a
characteristic pattern of growth in 33% of the
tumor; however, this feature was not observed in
any benign adrenal tumor (P  .001). Zero to 25%
clear tumor cell cytoplasm was not a specific man-
ifestation of malignancy, as 13.5% of adenomas
demonstrated this finding.
The frequency of 12 morphologic features among
benign and malignant adrenocortical tumors is
shown in Table 2. These adverse pathologic fea-
tures include tumor weight of 250 g; nuclear
Grade III or IV; necrosis; diffuse architecture;
0–25% clear cytoplasm; presence of capsular, ve-
nous, sinusoidal or adjacent organ invasion; mitotic
activity of 5 per 50 high-power fields; and mitotic
atypia. The number of adverse morphologic fea-
tures (morphologic index) was used in the analysis.
Immunohistochemical Profiling of Cell Cycle
Regulatory Proteins
See Table 3 for a summary of these profiles. The
patterns of p53 expression and those of important
related molecules, mdm-2, p21, and Bcl-2 were in-
vestigated. Expression patterns of two regulators of
cell cycle progression, cyclin D1 and p27, as well as
the cell proliferation marker, Ki-67, were evaluated
as well. The anti-p53 antibody detects wild-type
and mutated p53. The half-life and expression of
p53 protein is low and therefore undetectable by
immunohistochemistry. In malignant cells, most
p53 mutations lead to products that are not ubiqui-
tinated, accumulate in the nuclei, and can be dem-
onstrated by immunohistochemistry. Immunohis-
tochemical profiling of p53 expression
demonstrated absence of nuclear staining in all but
two (5.4%) adrenocortical carcinomas.
Although the majority of adrenal neoplasms
demonstrated nuclear staining for the inactivating
p53-binding protein, mdm-2, nuclear overexpres-
sion of this molecule was infrequent (28% overall).
The overexpression of mdm-2 among adrenocorti-
cal adenomas and carcinomas was not significantly
TABLE 2. Adrenal Adenoma versus Carcinoma,
Morphologic Features
Characteristic
Adenoma
(n  37)
n (%)
ACC (n  67)
n (%)
P
Median no. slides reviewed 4 (1–18) 14 (1–54) N/A
Median tumor weight, gm 50 (20–60) 576 (118–2500) 0.001
Tumor weight category, gm 0.001
0–100 37 (100%) 4 (9.1%)
101–250 0 (0%) 6 (13.6%)
251–1000 0 (0%) 25 (56.8%)
1000 0 (0%) 9 (20.5%)
Venous invasion 0.001
Yes 0 (0.0%) 28 (42.4%)
No 37 (100%) 38 (57.6%)
Capsular invasion 0.001
Yes 0 (0.0%) 34 (53.1%)
No 37 (100%) 30 (46.9%)
Sinus invasion 0.001
Yes 0 (0.0%) 63 (94.0%)
No 37 (100%) 4 (6.0%)
Adjacent organ invasion 0.03
Yes 0 (0.0%) 5 (7.6%)
No 37 (100%) 61 (92.4%)
Nuclear grade 0.001
1 2 (5.4%) 0 (0.0%)
2 30 (81.1%) 1 (1.5%)
3 5 (13.5%) 18 (26.9%)
4 0 (0.0%) 48 (71.6%)
Necrosis 0.001
Yes 0 (0.0%) 60 (89.6%)
No 37 (100%) 7 (10.4%)
Median mitotic rate/50 hpf 0 (0–1) 17 (0–178) 0.001
Mitotic rate/50 hpf
category
0.001
0–5 37 (100%) 14 (20.9%)
6–20 0 (0.0%) 22 (32.8%)
21–50 0 (0.0%) 24 (35.8%)
50 0 (0.0%) 7 (10.5%)
Atypical mitosis 0.001
Yes 0 (0.0%) 46 (68.7%)
No 37 (100%) 21 (31.3%)
Architecture 0.001
Diffuse 0 (0.0%) 55 (82.1%)
Non-diffuse 37 (100%) 12 (17.9%)
Clear cytoplasm 0.001
0–25% 5 (13.5%) 55 (82.1%)
26–100% 32 (86.5%) 12 (17.9%)
Microscopic resection
margin
0.001
Negative 37 (100%) 21 (33.3%)
Close 0 (0.0%) 4 (6.4%)
Positive 0 (0.0%) 14 (22.2%)
Unknown 0 (0.0%) 24 (38.1%)
Number of adverse
morphologic
features
Metastasizing
0 30 (81.1%) 0 0 (0%)
1 4 (10.8%) 0 0 (0%)
2 3 (8.1%) 0 0 (0%)
3 0 1 (1.5%) 0 (0%)
4 0 2 (3.0%) 1 (50%)
5 0 4 (6.0%) 2 (50%)
6 0 9 (13.4%) 7 (77.8%)
7 0 7 (10.4%) 7 (100%)
8 0 7 (10.4%) 6 (85.7%)
9 0 18 (26.9%) 16 (88.9%)
10 0 13 (19.4%) 12 (92.3%)
11 0 5 (7.5%) 5 (100%)
12 0 1 (1.5%) 1 (100%)
Numbers 67 indicate only those variables that could be determined
with certainty after review of the histopathology slides and pathology
reports.
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different (36% vs. 20%, P  .13). Nuclear p21 ex-
pression was present in both benign and malignant
adrenocortical tumors, although a significantly
lower proportion of adenomas manifested the p21-
positive phenotype (36% vs. 69%, P  .006).
The lowest rates of expression among the inves-
tigated markers were observed for the antiapoptotic
molecule, Bcl-2, and the regulator of the G1 check-
point of the cell cycle, cyclin D1. Low to absent
nuclear immunostaining for these two molecules
was identified in all benign and malignant adrenal
tumors. The highest rate of expression for both
benign and malignant adrenocortical tumors was
for the cyclin-dependent kinase inhibitor, p27 pro-
tein; however, a significantly lower proportion of
adenomas manifested the p27-positive phenotype
(69% vs. 94%, P  .009).
Tumor cell proliferative activity was evaluated by
immunostaining against the Ki-67 antigen. No pa-
tient with adrenocortical adenoma in this study
demonstrated a Ki-67–positive phenotype, defined
as 5% of tumor cells with nuclear immunoreac-
tivity. Ki-67 overexpression was present in 35% of
adrenocortical carcinomas (Fig. 1). Thus, differen-
tial molecular expression distinguished between
the benign and malignant adrenal tissue, as there
was statistically significant differential expression
of the following cell cycle regulatory proteins: Ki-67,
p21, and p27 (Table 3).
As no cases in this study demonstrated overex-
pression of Bcl-2 or cyclin D1, and only two cases
overexpressed p53, these markers have little value
in predicting adrenocortical tumor biology. Given
the moderate number of cases in the tissue mi-
croarray, we used the number of markers with un-
favorable expression pattern for analytic purposes.
Overexpression of Ki-67, p21, and p27 were predic-
tive of malignancy, and overexpression of mdm-2
correlated with benign adrenal tumors by univari-
ate analysis. Therefore, Ki-67 (), p21 (), p27 (),
or mdm-2 () was regarded as an unfavorable mo-
lecular expression pattern (Fig. 1). Each tumor
could have zero to four unfavorable molecular
markers. The number of unfavorable markers ex-
pressed was highly predictive of malignancy, as the
proportions of carcinomas expressing zero, one,
two, three, and four unfavorable molecular markers
were 0, 12%, 44%, 72%, and 100%, respectively (Ta-
ble 4, P  .001).
Morphologic and Molecular Correlations
A progressive increase in Ki-67 proliferative index
was observed with increasing mitotic rate (Table 5,
P  .001). No similar significant association was
evident between mitotic rate and either p21 (P 
0.7) or p27 (P  0.1). Ki-67 expression was signifi-
cantly associated with morphologic index, as Ki-67
overexpression was significantly greater for tumors
manifesting 5 than 5 of 12 adverse morphologic
features (Table 5, P  .001). Significant associations
also existed between the p27 expression and patho-
logic features (Table 5, P  .05), but no significant
association was found between p21 expression and
morphologic index (P .08). There were significant
associations between both mitotic rate (P  .001)
and morphologic index (P  .001) with number of
unfavorable molecular markers expressed (Table 6).
Morphologic and Molecular Predictors of
Metastatic Adrenocortical Carcinoma
At the time of last follow-up, 47 patients had died
of disease, 13 had died of other causes, 8 were alive
with distant metastases, 31 had no evidence of dis-
ease, and 5 were lost to follow-up. The majority
(57/67, 85%) of patients with adrenocortical carci-
noma developed distant metastasis. The number of
adverse morphologic features was associated with
risk of distant metastasis, as 43% of tumors dem-
onstrating five or fewer and 90% of those with more
than five pathologic features developed systemic
spread of disease (P  .01). Histological factors that
were significantly associated with distant metasta-
sis of adrenocortical carcinoma included the pres-
ence of tumor necrosis (P  .01), 5 mitosis/50 hpf
(P  .01), atypical mitoses (P  .05), and sinusoidal
invasion (P  .01). No statistically significant cor-
relation could be identified between distant metas-
tasis and any individual investigated molecular
markers. The number of unfavorable markers ex-
pressed was highly predictive of metastatic spread,
TABLE 3. Cell Cycle Regulator Expression in
Adrenocortical Adenoma versus Carcinoma
Molecular Marker
(positive percent cutoff)
Adenoma
(n  33)
n (%)
ACC
(n  38)
n (%)
P
Ki-67 (5%) 0.001
Negative 33 (100%) 20 (64.5%)
Positive 0 (0%) 11 (35.5%)
p53 (5%) 0.107
Negative 38 (100%) 35 (94.6%)
Positive 0 (0%) 2 (5.4%)
mdm-2 (50%) 0.131
Negative 21 (63.6%) 28 (80%)
Positive 12 (36.4%) 7 (20%)
p21 (10%) 0.006
Negative 21 (63.6%) 11 (30.6%)
Positive 12 (36.4%) 25 (69.4%)
p27 (30%) 0.009
Negative 10 (31.3%) 2 (5.6%)
Positive 22 (68.8%) 34 (94.4%)
Bcl-2 (10%) N/A
Negative 33 (100%) 38 (100%)
Positive 0 (0%) 0 (0%)
Cyclin D1 (5%) N/A
Negative 33 (100%) 38 (100%)
Positive 0 (0%) 0 (0%)
Number of patients in subgroup  total number in respective group
reflects tissue loss during specimen micro array processing.
Phenotyping of Adrenal Tumors (A. Stojadinovic et al.) 747
as the proportions of carcinomas with distant me-
tastases expressing zero, one, two, three, and four
unfavorable molecular markers were 0, 13%, 38%,
48%, and 75%, respectively.
DISCUSSION
The development of advanced cross-sectional im-
aging has led to earlier diagnosis of malignant adre-
nocortical tumors, thereby increasing the challenge of
differentiating benign from malignant pathology on
the basis of histomorphologic features alone (3, 23).
Most adrenocortical adenomas can be distinguished
from carcinomas by permanent section microscopy
based on well-defined, uniformly agreed-upon patho-
logic criteria (4–6). However, the specific histologic
diagnosis of adrenal neoplasms can be challenging.
Controversy exists over the usefulness of immunohis-
tochemical analysis of biomarkers in indeterminate
cases. The purpose of this study was to determine
whether immunohistochemical molecular profiling
based on tissue microarrays may identify markers
useful in distinguishing benign from malignant adre-
nocortical neoplasms. The pathologic criteria of Weiss
et al. (4) were applied in the present histopathological
analysis of adrenocortical neoplasms, and carcino-
mas were defined as tumors demonstrating three or
more histologic criteria. No adenoma studied demon-
strated venous, capsular, sinusoidal, or adjacent
organ invasion; tumor necrosis; or atypical mi-
FIGURE 1. Representative immunophenotypes according to type of adrenocortical tumor based on cell cycle regulatory proteins Ki 67, p27, and
p21. Immunopositivity is defined as nuclear staining for these three markers. Original magnification, 200.
TABLE 4. Association of Number of Unfavorable
Molecular Markers Expressed [Ki-67 (), p21 (), p27
(), mdm2 ()] with Adrenocortical Tumor Type
Tumor Type
Number of Unfavorable Markers
0 1 2 3 4
Adenoma 2 14 9 7 0
Carcinoma 0 2 7 18 4
Total 2 16 16 25 4
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totic figures. Mitotic rate 1 per 50 high-power
fields was specific for adrenocortical carcinoma.
Identification of the morphologic characteristics
requires pathologic experience with endocrine
neoplasms and meticulous examination of 50
high-power fields. Variable interobserver results
may occur in the quantification of mitotic activity,
the identification of atypical mitoses, and the as-
sessment of capsular and vascular invasion. We
have previously validated the currently applied
method of tissue microarrays for high-throughput
immunohistochemical analysis of proteins involved
in cell cycle regulation, cellular proliferation, and
apoptosis (18, 19, 24). Investigation of cell-cycle–
related molecules with this technique has been em-
ployed to study a variety of endocrine neoplasms
(6, 17–18).
The most frequently detected mutations in hu-
man malignancy involve the p53 tumor suppressor
gene (25, 26). Point mutations and/or deletions in-
activate p53, allowing unchecked progression of
cells containing damaged DNA through the S phase
of the cell cycle, thereby supporting the develop-
ment of a neoplastic phenotype (9, 10, 25, 26). This
and prior studies have demonstrated low to absent
p53 immunoreactivity in adrenal adenomas; how-
ever, the rate of immunopositivity among carcino-
mas has been highly variable, ranging from 5% in
this study to 52% (6, 9, 10, 15). This lack of repro-
ducibility among investigators makes it unlikely
that p53 alone is of practical use in differentiating
benign from malignant adrenocortical tumors. This
may be related to antibody selection, inability of the
antibody to recognize a protein with altered config-
uration, or antigen retrieval methodology.
Murine double minute (mdm-2) binds p53 and
induces its degradation and appears to be a com-
mon mechanism of p53 inactivation in human ma-
lignancy (27). Overexpression of mdm-2 was asso-
ciated with benign tumor biology in this study and
with normal adrenal histology in a prior study (6).
There were no significant differences in the mdm-2
positivity rate between adrenocortical adenomas
and carcinomas that precluded its use in the differ-
ential diagnosis. Wild-type p53 protein and p53-
independent cellular growth-promoting factors in-
duce overexpression of the cyclin-dependent
kinase inhibitor, p21, that leads to cell cycle arrest.
No relational pattern could be identified for p21
and mdm-2 overexpression in the same adrenal
tumors. However, this and a previous study found
significant differential expression of p21 among
normal, benign, and malignant adrenal tumors (6).
The absence of p21 overexpression has been asso-
ciated with adverse outcome in other solid-organ
tumors (28–30). The present data suggest that p21
is not sufficiently specific for the diagnosis of adre-
nal malignancy and that nor is it predictive of met-
astatic risk.
In adenomas as well as in carcinomas, there was
no overexpression of the anti-apoptotic molecule,
Bcl-2, and the regulator of the G1-S transition of the
cell cycle, cyclin D1. Cyclin D1 expression has been
found to be uniformly low among normal and neo-
plastic thyroid, parathyroid, and adrenal tissues;
Bcl-2 is overexpressed in thyroid and parathyroid,
unlike the case in adrenal tumors, underscoring the
marked variability of molecular expression among
endocrine neoplasms (6, 17, 18).
Up-regulation of the cyclin-dependent kinase in-
hibitor, p27, has been shown to result in cell-cycle
arrest and apoptosis (31, 32). Although a signifi-
cantly lower proportion of adenomas than carcino-
mas manifested the p27-positive phenotype in this
TABLE 5. Association of Ki-67, p21, and p27 Expression with Mitotic Rate and Morphologic Index
Marker
Morphologic Index Mitotic Rate/50 hpf
5 5 0–5 6–20 21–50 50
Ki-67 () 37 (71%) 15 (29%) 41 (79%) 7 (8%) 4 (13%) 0 (0%)
Ki-67 () 0 (0%) 11 (100%) 0 (0%) 3 (55%) 6 (27%) 2 (18%)
p21 () 21 (66%) 11 (34%) 22 (69%) 4 (12%) 5 (16%) 1 (3%)
p21 () 16 (44%) 20 (56%) 20 (56%) 7 (19%) 8 (22%) 1 (3%)
p27 () 10 (83%) 2 (17%) 11 (92%) 1 (8%) 0 (0%) 0 (0%)
p27 () 26 (47%) 29 (53%) 30 (54%) 10 (18%) 13 (24%) 2 (4%)
TABLE 6. Association of Number of Unfavorable Molecular Markers Expressed [Ki-67 (), p21 (), p27 (), mdm2 ()]
with Mitotic Rate and Morphologic Index
No. Factors
Morphologic Index Mitotic Rate/50 hpf
5 5 0–5 6–20 21–50 50
0 2 0 2 0 0 0
1 14 (88%) 2 (12%) 15 (94%) 1 (6%) 0 0
2 9 (56%) 7 (44%) 9 (56%) 3 (19%) 4 (25%) 0
3 11 (44%) 14 (56%) 14 (56%) 4 (16%) 6 (24%) 1 (4%)
4 0 (0%) 4 (100%) 0 1 2 1
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study, p27 immunostaining lacks the specificity to
be of any value in distinguishing between malig-
nant and benign adrenocortical tumors.
We evaluated adrenocortical tumor cell prolifer-
ation by nuclear Ki-67 immunostaining. No adre-
nocortical adenoma in this study demonstrated a
Ki-67–positive phenotype. High Ki-67 expression
was more frequently identified in adrenocortical
carcinoma than adenoma, supporting findings of
earlier studies and validating the value of this mo-
lecular marker in differentiating benign from ma-
lignant adrenocortical tumors (12, 13, 16). The as-
sociation between Ki-67 expression and mitotic
activity has been reported earlier by Nakazumi et al.
(16) and Goldblum et al. (12). The present study
supports and extends these findings to a large,
pathologically well-characterized cohort with adre-
nocortical neoplasms. The number of adverse mor-
phologic features displayed by the adrenocortical
tumor correlated significantly with expression of
Ki-67. This association has not been reported pre-
viously, possibly because of the relatively small
sample size of patients with adrenocortical carci-
noma in earlier studies (12–16). The morphologic
analogues of tumor cell proliferation as measured
by Ki-67 immunostaining appear to be mitotic ac-
tivity and the number of adverse pathologic fea-
tures expressed by the adrenocortical tumor. Be-
cause Ki-67 interpretation is less subjective than
mitotic count, it can be used by less experienced
morphologists and can lead to better interobserver
agreement in the diagnosis of malignancy in adre-
nocortical tumors.
We identified Ki-67, p21, and p27 overexpression
and mdm-2 underexpression to be associated with
adrenal malignancy. We found the criterion of
number (0 to 4) of unfavorable markers expressed
[Ki-67(), p21(), p27 (), mdm-2()] useful for
predicting malignancy. The phenotype Ki-67()
p21() p27 () mdm-2() was only seen in malig-
nant cases in this study. However, only 13% of
carcinomas expressed this phenotype. Among nine
cases with the Ki-67() p21() p27 () mdm-2()
phenotype, only one was malignant. Albeit few in
number, all p53() tumors were malignant. Al-
though specific, immunohistochemically defined,
multimolecular phenotypes can support the diag-
nosis of adrenocortical adenoma, they cannot be
relied upon for definitive diagnosis of adrenocorti-
cal carcinoma in the absence of supportive mor-
phologic criteria, because these molecular markers
are not sensitive enough even when combined.
Weiss et al. (5) defined specific morphologic
characteristics of adrenocortical carcinoma and
found that only mitotic activity correlated signifi-
cantly with patient survival. The majority of tumor-
related deaths associated with adrenocortical car-
cinoma occur as a result of distant spread of
disease. In this study, we correlated histopatholog-
ical and molecular parameters with risk of metas-
tasis in adrenocortical carcinomas. Although indi-
vidual marker expression did not provide insights
into the metastatic potential of adrenocortical car-
cinoma, the number of unfavorable markers ex-
pressed [Ki-67(), p21(), p27 (), mdm-2()] was
highly predictive of distant spread of disease. Tu-
mor morphology was the dominant determinant of
distant disease progression. Histological assess-
ment remains the cornerstone of the diagnosis and
assessment of biology for adrenocortical neoplasms
at the present time.
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